Triplet regimens have emerged as the standard of care for patients with relapsed multiple myeloma. Specifically, a 3-drug combination that stands out is daratumumab (Darzalex), lenalidomide (Revlimid), and bortezomib (Velcade), according to Andrew Kin, MD.
Chimeric antigen receptor (CAR) T-cell therapy has also shown promising activity in patients with relapsed/refractory disease. In a heavily pretreated patient population, updated data presented at the 2018 ASCO Annual Meeting showed that the BCMA-directed therapy bb2121 induced a complete response rate of over 50%. The median progression-free survival (PFS) was 11.8 months, with an over 10.8-month duration of response with bb2121. Phase II of the CRB-401 trial is ongoing.
“With a group of patients who were refractory and heavily pretreated, to see that level of response was almost unheard of,” said Kin of bb2121, adding that the plethora of available agents in this setting is a “good problem.”
... to read the full story